Nicolas Kerambrun, the Chief Executive Officer of AVA, delves into the journey of AVA Group, highlighting its commitment to transforming Mauritius into a major player in the medical device industry.
Featured in Investor’s Mag, 27th Edition, Dec 23 – March 24
Can you provide a brief overview of AVA Group and its primary business operations?
AVA group was formed in 2023, bringing together Natec Medical, Xtruline and Abiolabs as well as a real estate cluster and a foundation called ‘Dunes de Mer’, present in Madagascar where it works to improve the standard of living of local communities.
Its primary business operation is Natec Medical. Natec is specialized in the design, development and manufacturing of catheters intended for the global market. Natec is an Original Equipment Manufacturer (OEM) company, producing balloon catheters for cardiology, radiology, gastroenterology and urology.
With over 20 years of presence in Mauritius and having relocated from Boston in the United States, what key factors do you attribute to AVA Group’s success in the Mauritian market?
Natec was created in Boston, United States then moved to Mauritius in 2000. The key factor attributed to AVA success in Mauritius is clearly its people. The team is essentially made up of Mauritian employees, and international experts who ensure the transfer of know-how and boost innovation.
All this together creates a favorable ecosystem for the manufacturing of high tech, high quality products and value creation in Mauritius.
What prompted the identity change within your group this year?
AVA is fun, AVA is LIFE, AVA (to give life in Hebrew) saves lives. It was natural for us to bring together all entities and teams under a single brand ‘AVA’ to share our common vision. We are a purpose-driven group of companies, dedicated to delivering value and making a positive impact on life, for future generations.
AVA symbolizes our mission, to drive sustainable change for all by building pioneering businesses that promote better living.
How does AVA Group perceive the current trends and challenges in the medical device industry? Considering the global economic landscape, how do you assess the potential impact on the demand for medical devices?
The global economy landscape can be characterized by uncertainty, geopolitical instability, sanitary crisis, high investment costs and above all, a tremendous disruptive change in the job market. New generations need change and will lead this change.
In this context, the medical device industry is undergoing dynamic changes driven by innovation, regulatory shifts and healthcare needs.
Technological advancement and innovation will certainly increase the preference for minimally invasive surgical procedures. This surge will pressurize companies on precision, research, development and the quest for improved patient outcomes, such as recovery time, reduced hospitality stays…
The regulator must constantly adapt to these developments. The medical device industry is subject to stringent regulations. It serves to ensure product safety, quality and protect practitioners, above all, patients. It is also a major challenge for market entry. It is clear that companies that can anticipate regulatory complexities to obtain timely approvals from the authorities will have a competitive edge.
Healthcare needs, promoted by government policies on access to care, will reduce healthcare disparity, resulting in the constant increase in medical devices demand. Medical device industry continues to expand globally, this is particularly accurate for emerging markets.
The medical device industry has historically demonstrated steady growth, in terms of output growth from 3% to 6% per year over the past 3 years. This trend is expected to continue to reach 7% in 2028.
You mentioned that the market for medical devices is poised for exponential growth in Africa and Asia in the coming years. Can you provide further insights or evidence supporting this observation?
A constant and steady growth. To illustrate that, globally a compound annual growth rate of 4.17% is expected (CAGR 2023–2028), according to industry forecasts, 5.91% in Asia, 10% in Africa. The output in the medical devices and products market is projected to amount to Eur1.89tn in 2023. Asia and Africa outperform the global trend in growth, production output and value added.
Access to care as explained above, demographics and sociological factors will very likely amplify this phenomenon, globally and even more in Asia and Africa.
Mauritius aims to position itself as a Medical and Pharmaceutical hub, and you express confidence that Mauritius is well-positioned to become a major player in the medical device market. On what grounds do you believe Mauritius will be able to emerge as an important player in that segment?
Talking about the medical devices industry in Mauritius, yes, we are confident. The first medical device companies from the United States moved to Costa Rica in the 1970s. During that time, Costa Rica started attracting foreign investment in the medical device industry, and several US companies established their manufacturing operations in the country. This marked the beginning of Costa Rica’s emergence as a prominent destination for medical device manufacturing. In 2022, the main exported product from Costa Rica was medical equipment (including devices), the total value of these exports was nearly 4.1 billion U.S. dollars. The same occurred in Ireland, a country which holds a record for GDP per capita with USD107,000 in 2022.
All started with a policy of openness to international trade and foreign direct investment, together with investment in education and infrastructure. Mauritius has a stable political and economic environment, a skilled workforce, network of international trade agreements which give access to major markets and, supportive business environment. With 2023/24 Finance Law, Mauritius has taken a bold position in favor of the development of the medical devices industry.
For all these reasons, we firmly believe that the country is on the way of becoming a major player. That’s why we have decided to invest in the infrastructure to attract international players and create the ecosystem that enhances the growth of the industry.
AVA Technopark is designed to offer the most modern infrastructures, tools and services dedicated to international operators in the medical device sector, wishing to expand their activity to new markets, with the support of partners and local authorities, EDB, Landscope, Mexa.
Looking ahead, what are the key goals and aspirations of AVA Group in terms of industry leadership, market expansion, and technological advancements? Do you have plans for venturing into new markets?
We are already in the top 10 in catheter manufacturing companies. We aim to acquire a leadership position on our market in the next 3 years. To do this, we invest heavily in infrastructure, in our people and in the development of new products. We have plans to double our investment in innovation and focus on our people’s individual growth, in line with our values ‘LIFE’ for Leadership, Innovation, Family and Excellence.
We are also investing in projects which we firmly believe align with our vision. Partnerships and inorganic growth are not excluded in the coming years…
